The prevalence of hypertension is highly variable among population worldwide. Although control of hypertension has improved substantially over the past decade, 31% of people who are treated for hypertension are not controlled to a blood pressure (BP) level 140/90 mmHg. 1 The Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC8) defines hypertension as blood pressure (BP) greater than 140/90 mmHg in adults 18 years and older.
Prevalence of hypertension in India is reported to vary from 4-15% in urban and 2-8% in rural population. 3 It is estimated that the worldwide prevalence of hypertension would increase from 26.4% in 2000 to 29.2% in 2025. 4 Therefore, there is a need for more effective antihypertensive regimens that include simple single-pill fixed-dose combination (FDC) products.
The European Society of Hypertension and Cardiology, states that the primary goal of treatment is to achieve the maximum reduction in long-term total risk of cardiovascular morbidity and mortality. 5 More than 50% patients who do not response on monotherapy; require combination therapy for appropriate control of BP. 6 Targets are achieved in only a limited number of patients using monotherapy. Since hypertension is multifactorial disease, most patients require two or more antihypertensive agents with different mechanisms of action for the optimal management. 5, 7 This approach is also recommended by the Joint National Committee (JNC VIII)on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure .
Materials and Methods
This study was a post marketing, non-randomized, open, noncomparative,mono centric study. The fixed dose combination of Olmesartan 40 mg and Chlorthalidone 12.5 mg was administered to hypertensive patients once daily for 2 months (60 days). Informed consent was taken from the patients & the post marketing surveillance was in accordance with the principles in declaration of Helsinki and Good Clinical Practice (GCP).
Inclusion Criteria
Both male and female hypertensive patients aged >25 years old with seated cuff ≥160 mmHg and DBP ≥100 mmHg and who were willing to give informed consent were included.
Exclusion Criteria
Patients with any condition which in the opinion of the investigator makes the patient unsuitable for inclusion like; known or suspected secondary hypertension, history of asthma or angina, female patient who was pregnant or willing to get pregnant, and patients with known hypersensitivity to any of the ingredient of the fixed dose combination were excluded from the study.
Patient Distribution
Out of 30 patients 18 were female and 12 were male patients in the age range of 25-92years old (Table 1) .
Efficacy and safety evaluations
To evaluate the Efficacy following parameters were observed. 
Primary outcome measures:

Results
SBP and DBP were recorded. In addition, overall efficacy and tolerability was assessed at the end of the study period.
The baseline characteristics of patients are summarized in the Table 1 . Fig. 3 ). 
Achievement of JNC VIII goal
As per JNC VIII recommended target goal for patients>60 years old is 150/90 mmHg and 140/90 mmHg for patients of age <60 years. During and after the treatment following are the percentage of patients achieving the target BP goal. (Table 5 ) 
Global Assessment of Safety
Treatment was well tolerated and 3 out of 30 patients (10 %) complained about the side effects like headache, general weakness and dizziness.
Discussion
The prevalence of hypertension has risen dramatically in last three decades hence appropriate antihypertensive drug therapy is important. 8 Treatment goal of Hypertension is to control BP with minimum complications and adverse effects that improve the patient's quality of life. European guidelines and many other guidelines suggest the need of fixed dose combination therapy for the treatment of hypertension. 7, 9 On the basis of epidemiological studies using fixed dose combinations in a single pill represents in improving the control of hypertension and are efficient to achieve target goal of BP with no safety issues. 10, 11 Combination has synergistic and complementary mechanism of action and higher efficacy compared to monotherapy. 9 Ample evidences are available from the different clinical studies that multiple antihypertensive therapies are often required for effective control of blood pressure.
A clinical benefit of fixed drug combination in the management of hypertension has been already established. This study was conducted to evaluate the efficacy and safety of fixed dose combination of Olmesartan and Chlorthalidone in Indian patients.
There are no published studies of olmesartan in combination with chlorthalidone thus the results of the present study have shown encourage state with regard to the reduction in both SBP/DBP and in the achievement of target goal. Side effects were mild in natureand did not require discontinuation of therapy. Overall no safety concern for treatment was identified.
Conclusion
Fixed dose combination therapy of Olmesartan and Chlorthalidoneis an effective, safe and convenient treatment approach in controlling the blood pressure and achieving the desired blood pressure goal according to JNC VIII with patient adherence and compliance.
